Thanks, George.
That's very interesting as it shows that Benitec is of a pragmatic mindset and is prepared to use another company's technology (in this case Oxford BioMedica's lentivirus technology) which is already available rather than develop a new one of their own.
That sort of commercial arrangement would usually involve payment up front plus a royalty-fee should the end-product, "Nervana" (love the name!), come to market. I've never heard of the payment being an equity share in the borrowing company (ie Benitec). However, I'm certainly no guru and am no better informed than the next person so I might be completely wrong.
Whatever the case, I'm all in favour of small biotec companies using whatever technologies are to hand rather than spending money re-inventing the wheel.
News 
Market Data 
Discover 
